Brokerages Set Cryoport, Inc. (NASDAQ:CYRX) Price Target at $11.83

Shares of Cryoport, Inc. (NASDAQ:CYRX) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.83.

A number of research analysts recently issued reports on CYRX shares. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research note on Monday, March 31st. Roth Mkm reiterated a “buy” rating and set a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Finally, UBS Group upped their price objective on Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 19,830 shares of company stock worth $118,353 in the last 90 days. Corporate insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Bullseye Asset Management LLC boosted its holdings in Cryoport by 58.7% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock worth $1,737,000 after buying an additional 79,244 shares during the last quarter. Barclays PLC boosted its stake in shares of Cryoport by 272.9% in the third quarter. Barclays PLC now owns 81,417 shares of the company’s stock worth $660,000 after acquiring an additional 59,582 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Cryoport during the third quarter worth approximately $3,405,000. SG Americas Securities LLC raised its stake in Cryoport by 44.8% in the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock valued at $1,142,000 after purchasing an additional 45,430 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Cryoport by 2.9% in the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after purchasing an additional 1,764 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Trading Up 8.3 %

Cryoport stock opened at $5.36 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock has a market cap of $267.52 million, a PE ratio of -1.59 and a beta of 1.81. The stock has a 50-day moving average of $6.19 and a two-hundred day moving average of $7.13. Cryoport has a one year low of $4.58 and a one year high of $18.56.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the previous year, the business earned ($0.29) earnings per share. On average, research analysts anticipate that Cryoport will post -0.99 EPS for the current fiscal year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.